Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125297361 | 12529736 | 1 | I | 20160514 | 20160706 | 20160706 | PER | DE-LUPIN PHARMACEUTICALS INC.-2016-02158 | LUPIN | GHOSH S, NEUBERT J, NIEHUES T, ADAMS O, MORALI-KARZEI N, BORKHARDT A, LAWS H. INDUCTION MAINTENANCE CONCEPT FOR HAART AS INITIAL TREATMENT IN HIV INFECTED INFANTS. EUROPEAN JOURNAL OF MEDICAL RESEARCH. 2011;16:243-248. | 0.00 | I | UNK | Y | 0.00000 | 20160706 | MD | DE | DE |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125297361 | 12529736 | 1 | SS | ZIDOVUDINE. | ZIDOVUDINE | 1 | Unknown | 180 MG/SQUAREM OF BODY-SURFACE AREA | UNKNOWN | 0 | BID | ||||||||
| 125297361 | 12529736 | 2 | SS | NEVIRAPINE. | NEVIRAPINE | 1 | Unknown | 2X150-200 MG/SQUAREM | UNKNOWN | 0 | BID | ||||||||
| 125297361 | 12529736 | 3 | SS | NEVIRAPINE. | NEVIRAPINE | 1 | Unknown | 150-200 MG/SQUAREM | UNKNOWN | 0 | BID | ||||||||
| 125297361 | 12529736 | 4 | SS | NEVIRAPINE. | NEVIRAPINE | 1 | Unknown | 150-200 MG/SQUAREM | UNKNOWN | 0 | BID | ||||||||
| 125297361 | 12529736 | 5 | SS | Lopinavir | LOPINAVIR | 1 | Unknown | UNKNOWN | 0 | 300 | MG/M**2 | BID | |||||||
| 125297361 | 12529736 | 6 | SS | ABACAVIR. | ABACAVIR | 1 | Unknown | UNKNOWN | 0 | 8 | MG/KG | BID | |||||||
| 125297361 | 12529736 | 7 | SS | ABACAVIR. | ABACAVIR | 1 | Unknown | UNKNOWN | 0 | 8 | MG/KG | BID | |||||||
| 125297361 | 12529736 | 8 | PS | LAMIVUDINE. | LAMIVUDINE | 1 | Unknown | UNKNOWN | 205217 | 4 | MG/KG | BID | |||||||
| 125297361 | 12529736 | 9 | SS | LAMIVUDINE. | LAMIVUDINE | 1 | Unknown | UNKNOWN | 205217 | 4 | MG/KG | BID | |||||||
| 125297361 | 12529736 | 10 | SS | LAMIVUDINE. | LAMIVUDINE | 1 | Unknown | UNKNOWN | 205217 | 4 | MG/KG | BID |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125297361 | 12529736 | 1 | Antiretroviral therapy |
| 125297361 | 12529736 | 2 | Antiretroviral therapy |
| 125297361 | 12529736 | 5 | Antiretroviral therapy |
| 125297361 | 12529736 | 6 | Antiretroviral therapy |
| 125297361 | 12529736 | 8 | Antiretroviral therapy |
Outcome of event
| no results found |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125297361 | 12529736 | Blood alkaline phosphatase increased | |
| 125297361 | 12529736 | Blood creatine phosphokinase increased | |
| 125297361 | 12529736 | Gamma-glutamyltransferase increased |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |